Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of telisotuzumab adizutecan (ABBV-400) combinations in metastatic colorectal cancer
jRCT2031250013Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of telisotuzumab adizutecan in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Objective Response Rate (ORR) and Number of participants with adverse events. Started Jun 2025; status: recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on jRCT2031250013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250013.